Technical Analysis for BMRN - BioMarin Pharmaceutical Inc.

Grade Last Price % Change Price Change
grade A 126.06 -0.59% -0.75
BMRN closed down 0.59 percent on Friday, July 10, 2020, on 49 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.
Earnings due: Jul 30
*** please verify all earnings dates ***

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Strong Up Up Flat
Historical BMRN trend table...

Date Alert Name Type % Chg
MACD Bearish Signal Line Cross Bearish 0.00%
1,2,3 Pullback Bullish Bullish Swing Setup 0.00%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.00%
NR7 Range Contraction 0.00%
Inside Day Range Contraction 0.00%
Overbought Stochastic Strength 0.00%
Overbought Stochastic Strength -0.59%
New 52 Week Closing High Bullish -2.07%
Slingshot Bullish Bullish Swing Setup -2.07%
Overbought Stochastic Strength -2.07%

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

BioMarin Pharmaceutical Inc. develops and commercializes biopharmaceuticals for serious diseases and medical conditions in the United States, Europe, Latin America, and internationally. The company's commercial products include Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase enzyme used for the treatment of mucopolysaccharidosis VI; Kuvan, a proprietary synthetic oral form of 6R-BH4 used to treat patients with phenylketonuria (PKU), a metabolic disease; Aldurazyme used for the treatment of mucopolysaccharidosis I, a genetic disease; and Firdapse used to treat Lambert Eaton Myasthenic Syndrome, an autoimmune disease. It also develops Vimizim, an enzyme replacement therapy that is in phase III clinical stage for the treatment of MPS IVA, a lysosomal storage disorder; PEG-PAL, an enzyme substitution therapy that is under Phase II clinical trial to treat PKU; BMN-701, an enzyme replacement therapy, which is under Phase I/II clinical trials for Pompe disease, a glycogen storage disorder; BMN-673, a clinical Phase I/II trial product for the treatment of cancer; and BMN-111, a peptide therapeutic that is under Phase I clinical trial for the treatment of achondroplasia. The company sells its Naglazyme, Kuvan, and Firdapse products to specialty pharmacies and end-users, such as hospitals and foreign government agencies, which act as retailers; and Naglazyme products to distributors and pharmaceutical wholesalers. It has a collaboration agreement with Genzyme Corporation for the manufacture of Aldurazyme; and an agreement with Merck Serono S.A. for the further development and commercialization of BH4 in Kuvan for PKU and for other indications, and PEG-PAL. BioMarin Pharmaceutical Inc. was founded in 1996 and is headquartered in San Rafael, California.
Medicine Health Cancer Treatment Of Cancer Drug Discovery Rare Diseases Virotherapy Serious Diseases Autoimmune Disease Biopharmaceuticals Inborn Errors Of Metabolism Enzyme Replacement Therapy Phenylketonuria Pharmaceutical Wholesalers Pku Pompe Disease Achondroplasia Biomarin Pharmaceutical Genetic Disease Iduronidase Intellectual Disability Lambert Eaton Myasthenic Lambert Eaton Myasthenic Syndrome Novato

Is BMRN a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 129.89
52 Week Low 62.88
Average Volume 1,642,916
200-Day Moving Average 88.02
50-Day Moving Average 107.93
20-Day Moving Average 120.78
10-Day Moving Average 125.95
Average True Range 4.16
ADX 42.97
+DI 26.11
-DI 10.87
Chandelier Exit (Long, 3 ATRs ) 117.41
Chandelier Exit (Short, 3 ATRs ) 115.56
Upper Bollinger Band 135.81
Lower Bollinger Band 105.75
Percent B (%b) 0.68
BandWidth 24.89
MACD Line 5.90
MACD Signal Line 6.13
MACD Histogram -0.2302
Fundamentals Value
Market Cap 22.09 Billion
Num Shares 175 Million
EPS -1.07
Price-to-Earnings (P/E) Ratio -117.81
Price-to-Sales 12.04
Price-to-Book 5.17
PEG Ratio -4.46
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 129.68
Resistance 3 (R3) 129.73 128.57 129.08
Resistance 2 (R2) 128.57 127.64 128.54 128.88
Resistance 1 (R1) 127.31 127.07 126.73 127.27 128.68
Pivot Point 126.15 126.15 125.86 126.13 126.15
Support 1 (S1) 124.90 125.23 124.32 124.85 123.44
Support 2 (S2) 123.74 124.66 123.71 123.24
Support 3 (S3) 122.48 123.74 123.04
Support 4 (S4) 122.44